Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Data Points Received from the Doctors/ Gastrologist:
3.1.3 Data points received from the Manufacturer/ Pharmaceutical Companies:
3.1.4 Data points received from Hospitals, Clinics:
3.1.5 Secondary Research Methodology
3.1.6 Market Share Analysis
3.1.7 Trade Analysis
3.1.8 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing cases of smoking to boost the market growth (Impact weightage- 20%)
4.2.2 Rising cases of reflux disorder during pregnancy (impact weightage- 15%)
4.2.3 Changing lifestyle and irregular dietary habits (Impact weightage- 15%)
4.2.4 Increasing incidence of acid reflux disorder (heartburn) will boost the American GERD& NERD treatment market (Impact weightage- 25%)
4.2.5 Growing geriatric population (impact weightage- 15%)
4.2.6 Increasing demands for endoscopy biopsy procedures for early diagnosis (Impact weightage- 10%)
4.3 Restraints
4.3.1 Loss of patent exclusivity and lack of pipeline drugs (impact weightage- 55%)
4.3.2 High cost of the gastroscopes (weightage impact- 45%)
4.4 Opportunity
4.4.1 Development of new drugs
4.5 Mega Trends
4.6 Macroeconomic Indicators
4.7 Technology Trends & Assessment
5 Market Factor Analysis
5.1 Porters Five forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-Sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
6 Americas GERD & NERD Treatment Market, by Drug class
6.1 Introduction
6.2 Antacids (Acid Neutralizers)
6.3 Proton Pump Inhibitors
6.3.1 Esomeprazole
6.3.2 Omeprazole
6.3.3 Pantoprazole
6.3.4 Lansoprazole
6.3.5 Dexlansoprazole
6.3.6 Rabeprazole
6.4 H2 receptor blocker
6.4.1 Ranitidine
6.4.2 Famotidine
6.4.3 Cimetidine
6.4.4 Nizatidine
6.5 Pro kinetic agents
6.5.1 Domperidone
6.5.2 Metoclopramide
6.5.3 Itopride
6.5.4 Prucalopride
6.5.5 Cisapride
6.5.6 Benzamide
6.5.7 Mosapride
6.5.8 Erythromycin
6.6 Antidepressants
6.7 Calcium Channel Blockers
7 Americas GERD & NERD Treatment Market, by Dosage Form
7.1 Introduction
7.2 Solid
7.3 Liquid
8 Americas GERD & NERD Treatment Market, by End User
8.1 Introduction
8.2 Hospitals & Clinics
8.3 Research Centers
9 Americas GERD & NERD Treatment Market, by Region
10 Americas GERD & NERD Treatment Market, by Region
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 South America
11 Competitive Landscape
11.1 Introduction
11.2 Company Share Analysis
12 Company Profiles
12.1 AstraZeneca
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Products
12.1.4 Strategy
12.1.5 Key Developments
12.2 Addex Pharmaceuticals
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Products
12.2.4 Strategy
12.2.5 Key Developments
12.3 Takeda Pharmaceutical
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Products
12.3.4 Strategy
12.3.5 Key Developments
12.4 Eisai Co., Ltd
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Products
12.4.4 Strategy
12.4.5 Key Developments
12.5 Medigus Ltd
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Products
12.5.4 Strategy
12.5.5 Key Developments
12.6 RaQualia Pharma Inc
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Products
12.6.4 Strategy
12.6.5 Key Developments
12.7 Torax Medical
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Products
12.7.4 Strategy
12.7.5 Key Developments
12.8 Carbon Medical technologies
12.8.1 Company Overview
12.8.2 Financials
12.8.3 Products
12.8.4 Strategy
12.8.5 Key Developments
12.9 Endogastric Solutions
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Products
12.9.4 Strategy
12.9.5 Key Developments
12.1 Medtronic
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Products
12.10.4 Strategy
12.10.5 Key Developments
12.11 Pfizer
12.11.1 Company Overview
12.11.2 Financials
12.11.3 Products
12.11.4 Strategy
12.11.5 Key Developments
12.12 Novartis AG.
12.12.1 Company Overview
12.12.2 Financials
12.12.3 Products
12.12.4 Strategy
12.12.5 Key Developments
12.13 GlaxoSmithKline plc
12.13.1 Company Overview
12.13.2 Financials
12.13.3 Products
12.13.4 Strategy
12.13.5 Key Developments
12.14 Valeant Pharmaceuticals
12.14.1 Company Overview
12.14.2 Financials
12.14.3 Products
12.14.4 Strategy
12.14.5 Key Developments
12.15 Ironwood Pharmaceuticals, Inc.
12.15.1 Company Overview
12.15.2 Financials
12.15.3 Products
12.15.4 Strategy
12.15.5 Key Developments
13 Appendix
13.1 Discussion Blue Print
14 MRFR Conclusion
14.1 Key Findings
14.1.1 From CEO's View Point
14.1.2 Unmet Needs
14.2 Key companies to watch